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Abstract
Background: Quinupristin/dalfopristin (Q/D) is a valuable alternative antibiotic to vancomycin for the treatment of
multi-drug resistant Enterococcus faecium infections. However, resistance to Q/D in E. faecium clinical isolates and
nosocomial dissemination of Q/D-resistant E. faecium have been reported in several countries and should be of concern.
Results: From January 2012 to December 2015, 911 E. faecium clinical isolates were isolated from various specimens of
inpatients at the first Affiliated Hospital of Wenzhou Medical University located in Wenzhou, east China. Of 911 E. faecium
clinical isolates, 9 (1.0 %, 9/911) were resistant to Q/D, with the Q/D MIC values of 64 mg/L(1), 32 mg/L(1), 16 mg/L(3),
8 mg/L(1) and 4 mg/L(3) determined by broth microdilution. All Q/D-resistant isolates were susceptible to vancomycin,
tigecycline and teicoplanin but resistant to penicillin, ampicillin and erythromycin. vatE was only found in one
Q/D-resistant E. faecium isolate while vatD was not detected in any of the isolates tested. 8 of 9 Q/D-resistant E.
faecium isolates were found be positive for both ermB and msrC. The combinations of Q/D resistance determinants
were ermB-msrC (7 isolates) and ermB-msrC-vatE (one isolate). ST78, ST761, ST94, ST21 and ST323 accounted for 4, 2, 1, 1
and 1 isolate, respectively, among which ST78 was the prevalent ST.
Conclusion: Q/D-resistant E. faecium clinical isolates were first described in China. Carriage of vatE, ermB and msrC was
responsible for Q/D resistance.
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Background
Enterococci, which are the normal commensals in the in-
testinal tract of humans and animals, are the common
cause of nosocomial infections. Enterococcus faecalis
and Enterococcus faecium are responsible for most of
enterococcal infections, such as urinary-tract infections,
intra-abdominal infections, bacteremia, and endocarditis
[1]. With an intrinsic and acquired resistance to some
antimicrobial agents, Enterococci have become important
nosocomial pathogens [2]. Infections caused by multidrug
-resistant Enterococci, especially multiple resistances to
vancomycin, penicillin, and aminoglycoside (high-level
resistance), are of a major concern, making enterococ-
cal infections a serious and life-threatening disease [1].
Increase of vancomycin-resistant Enterococci (VRE) limits
the selection of vancomycin for treatment of enterococcal
infections. Therefore, attention has been directed toward
the alternatives for the treatment of enterococcal infec-
tions, especially VRE infections.
Quinupristin/dalfopristin(Q/D) is a combination of
streptogramins B (quinupristin) and streptogramins A
(dalfopristin) at 30:70 ratio. Streptogramins A and B are
bacteriostatic when used separately but act synergistic-
ally when combined. The synergic behavior of the com-
bination results in Q/D rapidly bactericidal against the
majority of Gram-positive organisms [3]. Clinically, Q/D
is mainly used for the treatment of infections caused by
multidrug-resistant Gram-positive cocci [4, 5]. Q/D is ef-
fective against E. faecium, but not against E. faecalis [6].
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As E. faecalis isolates possess a chromosomal gene named
lsa responsible for lincosamide and streptogramin A re-
sistance, which results in all E. faecalis with intrinsic re-
sistance to Q/D [2]. Q/D has been successfully used for
the treatment of vancomycin-resistant E. faecium (VREf)
infections [7, 8]. The combination of Q/D and high-dose
ampicillin was used successfully for treating persistent
bacteremia and endocarditis caused by VREf [5, 9]. Q/D is
a valuable alternative to vancomycin for the treatment of
multi-drug resistant E. faecium infections. However, resist-
ance to Q/D in E. faecium clinical isolates and nosocomial
dissemination of Q/D-resistant E. faecium have been
found in several countries [10–13]. Although the preva-
lence of Q/D resistance among these isolates from humans
is still low, emergence and dissemination of Q/D-resistant
E. faecium limit the therapeutic option of successful treat-
ment of VREf infections. However, Q/D resistance among
E. faecium isolates from inpatients has not been reported
in China. The aim of the present study was to elucidate the
prevalence of Q/D resistance among E. faecium isolates
from the various specimens of inpatients at a tertiary
teaching hospital between January 2012 and December
2015.
Methods
Collection of clinical isolates and E. faecium identification
From January 2012 to December 2015, a total of 911
non-duplicate E. faecium isolates (single isolate per pa-
tient) from various specimens of inpatients in the first
Affiliated Hospital of Wenzhou Medical University lo-
cated in Wenzhou, east China, were collected consecu-
tively for investigating the prevalence of Q/D resistance.
When multiple E. faecium isolates were isolated from
the same patient, the first isolated strain was included.
The included isolates were identified as E. faecium using
Gram’s stain, catalase test and Vitek-2 microbiology
analyzer (bioMe’rieu, Marcy l’Etoile, France). Q/D-resistant
isolates were re-identified as E. faecium using Matrix-
Assisted Laser Desorption/ Ionization Time of Flight
Mass Spectrometry (MALDI-TOF-MS) (bioMe’rieux, Marcy
l’Etoile, France) and PCR amplifying 16S rRNA gene. S. aur-
eus ATCC25923, Escherichia coli ATCC25922 and Pseudo-
monas aeruginosa ATCC27853 were used as control strains
for identification of bacteria. The Ethics Committee of the
first Affiliated Hospital of Wenzhou Medical University
exempted this study from review because the present study
focused on bacteria.
Antimicrobial susceptibility testing
The antimicrobial susceptibility testing for E. faecium
clinical isolates was determined by Vitek-2 microbiology
analyzer (bioMe’rieu, Marcy l’Etoile, France) in accord-
ance with the manufactory’s instructions. Q/D resistance
initially determined by Vitek-2 microbiology analyzer
was reconfirmed using disk diffusion method were ac-
cording to the guidelines provided by the Clinical and
Laboratory Standards Institute (CLSI) [14]. Q/D mini-
mum inhibitory concentration (MIC) values for Q/D-
resistant E. faecium clinical isolates were determined
twice using broth microdilution method operated by two
separate operators in accordance with the guidelines rec-
ommended by CLSI [14]. Q/D (Synercid, Astellas Pharma,
Inc.) was kindly provided by Pro. Nobumichi Kobayashi
from Sapporo Medical University (Japan). S. aureus
ATCC25923, E. coli ATCC25922 and P. aeruginosa
ATCC27853 were used as control strains for antimicrobial
susceptibility testing.
Detection of determinants responsible for Q/D resistance
The genes responsible for resistance to streptogramin B
antibiotics including erm (ermA, ermB and ermC) and
msrC, and streptogramin A antibiotics including vat (vatD
and vatE) were detected by PCR assays with specific
primers and reaction conditions described previously
[15–17]. DNA sequencing was used for the identifica-
tion of genotype of the genes tested.
Multi-locus sequence typing (MLST)
MLST of E. faecium isolates was performed using ampli-
fication of internal fragments of the seven housekeeping
genes including adk , atpA , ddl , gyd, gdh, purK and pstS
of this organism as described previously [18]. Following
purification and sequencing of these genes, the sequences
were compared with the existing sequences available on the
MLST website for E. faecium (http://efaecium.mlst.net),
and STs were determined according to the allelic profiles.
Results and discussion
Prevalence of Q/D resistance among E. faecium clinical
isolates
Among 911 E. faecium clinical isolates over the study
period, 9 (1.0 %, 9/911) were resistant to Q/D determined
by the Vitek-2 Automated Microbiology Analyzer with
GPS card and disk diffusion method. The Q/D MIC values
for 9 Q/D-resistant E. faecium clinical isolates determined
by broth microdilution method were as follows: 64 mg/L,
1; 32 mg/L, 1; 16 mg/L, 3; 8 mg/L, 1 and 4 mg/L, 3
(Table 1). All Q/D-resistant isolates were susceptible to
vancomycin, tigecycline and teicoplanin but resistant to
penicillin, ampicillin and erythromycin. Eight (88.9 %) of 9
isolates with Q/D resistance were resistant to moxiofloxa-
cin, levofloxacin and ciprofloxacin. Five, 1 and 5 isolates
were resistant to gentamicin (high-level resistance), linez-
olid and nitrofurantoin, respectively (Table 1). As Q/D is
not available in China, the patients infected by these
Q/D-resistant E. faecium isolates were not subject to
be treated by Q/D. Therefore, we speculate that the ac-
quisition of Q/D resistance among E. faecium clinical
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isolates in the present study was not associated with
the consumption of Q/D. The previous study reported
that the extensive in-feed use of virginiamycin showed
full cross-resistance with Q/D selected for streptogramin-
resistant enterococci and resulted in a reservoir of resist-
ance genes in production animals [19]. Q/D resistance
determinants from animal-associated enterococcal iso-
lates can spread to E. faecium human isolates [20].
However, in the present study, it remains unknown
whether these Q/D-resistant E. faecium clinical isolates
was indeed associated with the isolates from animals.
To our knowledge, the present study is the first report
of Q/D resistance among E. faecium clinical isolates in
China. Up to now, although the prevalence of Q/D re-
sistance among E. faecium clinical isolates was very
low, the intermediate resistance to Q/D was relatively
high. A investigation from Japan reported that none was
resistant to Q/D while 28 (17.6 %, 28/159) were intermedi-
ate resistant to this antimicrobial agent (MIC = 2 mg/L)
among 159 E. faecium isolates from clinical specimens in a
Japanese hospital from 1997 to 2006 [21]. A study from
Greek reported that 250 of 865 (28.9 %) E. faecium isolates
from patients of eight Greek hospitals between 2005
and2006 were intermediate-resistant to Q/D (MICs = 1.5–
4 mg/L) [22]. In another report, all 60 primary clinical iso-
lates of E. faecium with resistance to glycopeptides were
fully susceptible to Q/D, with MIC50 and MIC90 values of
1.0 mg/L and 1.5 mg/L [23]. These previous studies and
our study support the evidence that Q/D is still an effective
and valuable antimicrobial agent for treating infections
caused by multi-resistant E. faecium, even VREf. Neverthe-
less, the emergence of Q/D resistance, especially increased
intermediate resistance to this antimicrobial agent, has be-
come a concern. Moreover, a high prevalence (10.0 %) of
Q/D resistance among E. faecium clinical isolates was
found in Korea, which was associated with both clonal
spread and the sporadic emergence of Q/D-resistant
isolates [12]. Hsueh et al. also reported a similar high
prevalence (9 %) of Q/D resistance among vancomycin-
resistant E. faefium clinical isolates in Taiwan [24]. As
our study did not investigate the prevalence of inter-
mediate resistance to Q/D among E. faecium clinical
isolates, it remains unclear whether there was a trend
of increase in intermediate resistance to Q/D, which
should be further investigated.
Determinants of Q/D resistance among E. faecium clinical
isolates
The resistance to Q/D is associated with enzymatic modi-
fication of the antibiotic, active transport or efflux medi-
ated by an ATP-binding protein, and alteration of the
target site [6]. Both resistance to streptogramin A and
streptogramin B is necessary for occurrence of Q/D resist-
ance [25]. Carriage of more than one streptogramin A re-
sistance gene (vat or vga) is necessary for the occurrence
of Q/D resistance in an organism [6]. The streptogramin
A resistance genes found in E. faeciumare were vatD and
vatE encoding acetyltransferases [6]. Modification of dal-
fopristin by the acetyltransferases VatD and VatE renders
it ineffective, abolishing the synergy with quinupristin.
vatD was initially found in an E. faecium isolate from a
hospitalized patient in Europe [26].vatD and vatE have
been found in E. faecium animal and human isolates in
Europe, USA and Korea [6, 27, 28]. In contrast, some
studies reported that none of the genes involved in the
expression of dalfopristin resistance (vatD, vatE, vgaA
and vgaB) were found in any Q/D-intermediate-resistant
or -resistant E. faecium isolates [21, 22, 27]. Similarly,
in the present study, vatE was only found in one Q/D-
resistant E. faecium isolate while vatD was not detected
in any of the isolates tested (Table 1). The most commonly
known resistance to streptogramin B in enterococci is the
macrolides, lincosamides, and streptogramins B ( MLSB)
resistance conferred by the erm genes (ermA, ermB and
ermC) encoding an enzyme that dimethylates an adenine
residue in the 23S rRNA, which results in decreased
Table 1 The characteristics of Q/D-resistant E. faecium isolates
No. Specimen ST Q/D MIC value
(mg/l)
Antimicrobial resistance profilea Antimicrobial susceptibility profilea Q/D resistance
determinants
1 pus 78 16 MOX, GEN(H), P, E, LZD, F, LEV, AMP, CIP TEC, TGC, TET, VAN ermB, msrC
2 urine 78 32 MOX, GEN(H), P, E, LEV, AMP, CIP LZD, TEC, F, TGC, TET, VAN ermB, msrC
3 catheter 94 16 GEN(H), P, E, LEV, AMP, CIP, MOX, LZD, TEC, F, TGC, TET, VAN
4 exudate 761 8 P, E, AMP LEV, CIP, MOX, GEN(H), TEC, F, TGC, TET, VAN, LZD ermB, msrC
5 wound 21 64 MOX, GEN(H), P, E, F, LEV, AMP, CIP LZD, TEC, TGC, TET, VAN ermB, msrC, vatE
6 exudate 323 4 MOX, P, E, F, LEV, AMP, CIP GEN(H), LZD, TEC, TGC, TET, VAN ermB, msrC
7 urine 78 4 MOX, P, E, LEV, AMP, CIP GEN(H), LZD, F, TEC, TGC, TET, VAN ermB, msrC
8 blood 761 16 MOX, P, E, LEV, AMP, CIP, TET, F GEN(H), LZD, TEC, TGC, VAN ermB, msrC
9 tissue 78 4 MOX, GEN(H), P, E, LEV, AMP, CIP, F LZD, TEC, TGC, TET, VAN ermB, msrC
aP penicillin, AMP ampicillin, E erythromycin, TET tetracycline, TGC tigecycline. GEN(H) high-level gentamicin, CIP ciprofloxacin, MOX moxifloxacin, LEV levofloxacin,
F nitrofurantoin, LZD linezolid, VAN vancomycin, TEC teicoplanin
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binding of these antimicrobial agents [6]. In the present
study, ermB was found among 8 of 9 Q/D-resistant E.
faecium isolates. vgbA encoding a streptogramin-
inactivating enzyme (lyase) has been found rarely in the
isolates of E. faecium, but msrC conferring resistance to
streptogramin B antibiotics by active transport is com-
monly found in E. faecium isolates [29]. In the present
study, 8 of 9 Q/D-resistant E. faecium isolates were found
be positive for msrC. The remaining one isolate was nega-
tive for all resistance genes tested. Currently, there has not
been reported the combination of multiple streptogramin
A resistance genes in E. faecium. However, combinations
of the vatD-vgbA and ermB-vatD or vatE genes were
found in Q/D-resistant isolates [10, 30, 31]. The vatE was
more common than vatD in animal sources [11, 28, 32]. In
the present study, the combinations of Q/D resistance
determinants were ermB-msrC (7 isolates) and ermB-
msrC-vatE (one isolate).
Molecular characteristics of Q/D-resistantE. Faecium clinical
isolates
The lineage clonal complex 17 (CC17) (ST17, ST18, and
ST78) significantly associated with hospital infections
emerges as the high-risk clone responsible for the world-
wide spread of VERf [33]. A report from Poland showed
the domination of representatives of lineages ST78 and
ST17/18 (52.7 and 46.4 %, respectively) among consecu-
tive E. faecium clinical isolates collected in 30 hospitals
between May 2010 and June 2011 through prospective
surveillance in Poland [34]. VERf isolates from 10 in-
fected and 40 colonized inpatients from a single hospital
in the north of Spain were assigned to ST17 by MLST
[35]. In China, ST78 was the predominant MLST type
among VERf clinical isolates [36]. However, the molecular
characteristic of Q/D-resistant E. faecium clinical isolates
is limited. Among 25 Q/D-resistant E. faecium isolates
from Korea, 10, 9 and 4 belonged to ST78, ST192 and
ST203, respectively, with ST78 being the prevalent ST
[12]. In the present study, among 9 Q/D-resistant isolates,
ST78, 761, 94, 21 and 323 accounted for 4, 2, 1, 1 and 1
isolate, respectively, with ST78 being the prevalent ST
(Table 1). In another report, 5 STs including four STs of
CC17 were identified in Q/D-intermediate resistant E. fae-
cium clinical isolates [21]. In addition, only a VERf isolate
from China was found to belong to ST323 [37]. The
present study is the second report of an E. faecium ST323
isolate with Q/D resistance associated with bloodstream
infection.
Conclusion
In the present study, Q/D-resistant E. faecium clinical
isolates were first described in China. We also identified
that carriage of vatE, ermB and msrC was responsible
for Q/D resistance in E. faecium clinical isolates.
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